Key insights
- The author suggests Trulieve (TRUL) is a long-term value play due to cannabis rescheduling, its focus on medical marijuana, and strong management. While not yet profitable and facing regulatory hurdles, the author believes Trulieve has the potential to become a leader in the medical cannabis market if regulations ease. Bullish sentiment is expressed.
I think $Trul at a approx 2B MC is a value play for long term investors. They have been given sort of a head start by cannabis rescheduling. 85% of their products sold is medical MJ, its an healthcare play.
It will take time for regulations to change such as safe banking and federal legalization but if that happens they have the potential to be the Starbucks of medical cannabis.
Not profitable yet, and revenues hasnt increased due to the government red tape, but they have a lot of FCF, strong experienced management and a gift from the US government this week to pull away from
the competition. I could be wrong but im bullish.